SCHEMBL5142085

SCHEMBL5142085

CC1(C(N)=O)Oc2ccccc2C(C)(C)C1(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 3/20 0.32
MEN1 O00255 3/20 0.32
MAPT P10636 3/20 0.32
KMT2A Q03164 3/20 0.32
LMNA P02545 2/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
ATM Q13315 1/20 0.32
RECQL P46063 2/20 0.31
HPGD P15428 1/20 0.31
BLM P54132 1/20 0.31
SMAD3 P84022 1/20 0.31
PRMT1 Q99873 1/20 0.31
ACE2 Q9BYF1 1/20 0.31
FTO Q9C0B1 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
BACE1 P56817 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8051377 0.85 CYP2C19 (0.36) CYP2C19CYP2C9MAPK1HTTMEN1
SCHEMBL8607562 0.77 CYP2C19 (0.37) CYP2C19CYP2C9MAPK1HTTMEN1
SCHEMBL17372976 0.74 MEN1 (0.33) CYP2C19CYP2C9MAPK1HTTMEN1
SCHEMBL13589118 0.74 KDM4E (0.30) CYP2C19CYP2C9MAPK1ATM
SCHEMBL1536061 0.73 CYP2C19 (0.33) CYP2C19CYP2C9MAPK1HTTMEN1
SCHEMBL30528258 0.73 CYP2C19 (0.33) CYP2C19CYP2C9MAPK1HTTMEN1
SCHEMBL26037139 0.72 HTT (0.33) HTTMAPTALDH1A1HPGD
SCHEMBL27941800 0.72 CHRM3 (0.33) CYP2C19CYP2C9MAPK1HTTATM
SCHEMBL17144163 0.70 KCNE1 (0.31)
SCHEMBL5886685 0.70 THRB (0.38) CYP2C19CYP2C9MAPK1HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291641-B2 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-11-06 US disclosed
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments IPSEN PHARMA S.A.S. (FR) 2005-02-17 US disclosed
EP-1223933-A2 5-MEMBERED HETEROCYCLE DERIVATIVES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-24 EP disclosed
WO-2001026656-A2 5-MEMBERED HETEROCYCLE DERIVATIVES AND USE THEREOF AS MONOAMINE OXIDASE INHIBITORS SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038087-A1 Derivatives of heterocycles with 5 members, their preparation and their use as medicaments OXER1, OPRL1, OPRK1 CYP2C19 226/4885CYP2C9 145/4885MAPK1 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.